Compare GLU & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | ALDX |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 101.1M |
| IPO Year | N/A | 2014 |
| Metric | GLU | ALDX |
|---|---|---|
| Price | $19.25 | $1.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 9.3K | ★ 891.7K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.53 | $1.07 |
| 52 Week High | $21.69 | $6.18 |
| Indicator | GLU | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 36.50 |
| Support Level | $19.20 | $1.48 |
| Resistance Level | $20.17 | $1.88 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 36.61 | 12.68 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.